Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25:486–541.
Google ScholarÂ
Verduijn J, Coutant K, Fane ME, Galluzzi L. Molecular mechanisms of immune cell death in immunosenescence. Cell Death Differ. 2025;32:1755–62.
Google ScholarÂ
Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O, et al. Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol. 2008;20:504–11.
Google ScholarÂ
Chen R, Zou J, Liu J, Kang R, Tang D. DAMPs in the immunogenicity of cell death. Mol Cell. 2025;85:3874–89.
Google ScholarÂ
Galluzzi L, Kepp O, Zitvogel L, Tang D, Kroemer G. Cancer cell death: Cell-autonomous and immunogenic dimensions. Cancer Cell. 2026;44:281–305.
Google ScholarÂ
Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005;202:1691–701.
Google ScholarÂ
Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13:54–61.
Google ScholarÂ
Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050–9.
Google ScholarÂ
Yatim N, Jusforgues-Saklani H, Orozco S, Schulz O, Barreira da Silva R, Reis e Sousa C, et al. RIPK1 and NF-kappaB signaling in dying cells determines cross-priming of CD8(+) T cells. Science. 2015;350:328–34.
Google ScholarÂ
Wang Q, Wang Y, Ding J, Wang C, Zhou X, Gao W, et al. A bioorthogonal system reveals antitumour immune function of pyroptosis. Nature. 2020;579:421–6.
Google ScholarÂ
Aaes TL, Kaczmarek A, Delvaeye T, De Craene B, De Koker S, Heyndrickx L, et al. Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity. Cell Rep. 2016;15:274–87.
Google ScholarÂ
Zhang Z, Zhang Y, Xia S, Kong Q, Li S, Liu X, et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature. 2020;579:415–20.
Google ScholarÂ
Wang D, Zhang T, Shao Q, Wu X, Zhao X, Zhang H, et al. GSDME-mediated pyroptosis in microglia exacerbates demyelination and neuroinflammation in multiple sclerosis: insights from humans and cuprizone-induced demyelination model mice. Cell Death Differ. 2025;32:2368–83.
Google ScholarÂ
Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375:1254–61.
Google ScholarÂ
Tang D, Kroemer G, Kang R. Targeting cuproplasia and cuproptosis in cancer. Nat Rev Clin Oncol. 2024;21:370–88.
Google ScholarÂ
Liu YT, Chen L, Li SJ, Wang WY, Wang YY, Yang QC, et al. Dysregulated Wnt/beta-catenin signaling confers resistance to cuproptosis in cancer cells. Cell Death Differ. 2024;31:1452–66.
Google ScholarÂ
Du ZB, Wu XM, Lei JM, Cai YX, He J, Qian B, et al. SIRT3 deacetylates STEAP4 to modulate cuproptosis sensitivity via mitochondrial metabolic reprogramming in HBV-related HCC. Cell Death Differ. 2026; https://doi.org/10.1038/s41418-026-01713-w. Online ahead of print.
Liu J, Cai X, Lin J, Zhang Z, Zhou Q, Zhang X, et al. Extracellular GPX4 impairs antitumor immunity via dendritic ZP3 receptors. Cell. 2026;189:1056–1073.
Lei G, Lu Z, Xu Z, Braun C, Huo D, Gao J, et al. Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance. Cell. 2026; https://doi.org/10.1016/j.cell.2026.05.036. Online ahead of print.
Liu J, Liu Y, Wang Y, Kang R, Tang D. HMGB1 is a mediator of cuproptosis-related sterile inflammation. Front Cell Dev Biol. 2022;10:996307.
Google ScholarÂ
Wang W, Green M, Choi JE, Gijon M, Kennedy PD, Johnson JK, et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569:270–4.
Google ScholarÂ
Korman AJ, Garrett-Thomson SC, Lonberg N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat Rev Drug Discov. 2022;21:509–28.
Google ScholarÂ
Kang R, Liu J, Wang J, Kroemer G, Tang D Translating ferroptosis into oncology: challenges, opportunities and future directions. Nat Rev Clin Oncol. 2026;23:401-424.
Luan M, Zhu W, Feng Z, Jing F, Xing Y, Ma X, et al. MTF1 attenuates ferroptosis and cuproptosis synergistic potentiation in gastric cancer. Cell Death Differ. 2026;33:1103–19.
Google ScholarÂ
